DURHAM, N.C. & SEATTLE-- November 13, 2023--Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection. The...
Bayhill focused on the translation of research into therapeutics for the treatment of autoimmune diseases. The company pursued DNA-antigen vaccines and oligonucleotides that were specifically designed to promote immune intolerance. The company was dissolved in 2012.
Bayhill Therapeutics
San Mateo, CA
© 2023 Pappas Capital, LLC. ALL RIGHTS RESERVED.